

ASH 2025

67th ASH Annual Meeting and Exposition

December 6–9, 2025

Orlando, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.

ASH 2025: Top abstracts in MPN

December 6–9, 2025

Oral presentations: Saturday, December 6

| Abstract | Title | Presenter | Time (EST) |
|-----------------------------------|--|-------------------|-------------|
| 80 View | Efficacy and safety results from the primary analysis of the pivotal Summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis | Lindsay Rein | 09:45–10:00 |
| 81 View | Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study | Andrew Kuykendall | 10:00–10:15 |
| 83 View | Efficacy and safety of the LSD1 inhibitor bomedemstat in participants with polycythemia vera (PV) resistant or intolerant to cytoreductive therapy: The phase 2 Shorespan-004 study | Lindsay Rein | 10:30–10:45 |

Oral presentations: Sunday, December 7

| Abstract | Title | Presenter | Time (EST) |
|------------------------------------|--|------------------------|-------------|
| 482 View | Preliminary data from the phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis | John Mascarenhas | 09:45–10:00 |
| 484 View | Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global phase 1 studies | John Mascarenhas | 10:15–10:30 |
| 485 View | Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study | Jean-Jacques Kiladjian | 10:30–10:45 |
| 486 View | Fedora preliminary analysis of a phase II study evaluating the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis | Mary Frances McMullin | 10:45–11:00 |

Oral presentations: Monday, December 9

| Abstract | Title | Presenter | Time (EST) |
|------------------------------------|--|---------------|-------------|
| 909 View | Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the phase 2 RESTORE trial | Ciro Rinaldi | 15:15–15:30 |
| 910 View | Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: 96-week results from the phase III MANIFEST-2 study | Raajit Rampal | 15:30–15:45 |

| | | | |
|----------------------------|---|----------------|-------------|
| 1021 View | MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver” | Florian Heidel | 16:30–16:45 |
| 1022 View | Avapritinib treatment of patients with advanced systemic mastocytosis: 4-year safety, effect on bone and first-line efficacy results of the PATHFINDER clinical study | Andreas Reiter | 16:45–17:00 |
| 1024 View | Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia | Vikas Gupta | 17:15–17:30 |

| Posters | | | |
|----------------------------|--|----------------------|-----------------------------------|
| Abstract | Title | Presenter | Date and time (EST) |
| 2019 View | Pacritinib in patients with high-risk myelofibrosis: Outcomes from <i>post-hoc</i> analyses of two phase 3 studies | Pankit Vachhani | Saturday, December 6, 17:30–19:30 |
| 2023 View | Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: <i>Post hoc</i> analyses of SIMPLIFY-1 and MOMENTUM | Stephen Oh | Saturday, December 6, 17:30–19:30 |
| 2025 View | Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the phase 3 SIMPLIFY-1 trial | Stephen Oh | Saturday, December 6, 17:30–19:30 |
| 2051 View | A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant-selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia | Jason Gotlib | Saturday, December 6, 17:30–19:30 |
| 2052 View | ImproveMF: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis | John Mascarenhas | Saturday, December 6, 17:30–19:30 |
| 3794 View | Interim analysis of PROMise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib | Adam Mead | Sunday, December 7, 18:00–20:00 |
| 3795 View | The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results | Prithviraj Bose | Sunday, December 7, 18:00–20:00 |
| 3803 View | Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis | Prithviraj Bose | Sunday, December 7, 18:00–20:00 |
| 3804 View | Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II FAMy trial | Haifa Kathrin Al-Ali | Sunday, December 7, 18:00–20:00 |

| | | | |
|----------------------------|---|------------------|------------------------------------|
| 3809 View | Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor-naïve myelofibrosis patients treated with ruxolitinib | Vikas Gupta | Sunday, December 7, 18:00–20:00 |
| 3810 View | Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study | Naveem Pemmaraju | Sunday, December 7, 18:00–20:00 |
| 5527 View | Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF) | Chiara Paoli | Monday, December 8, 18:00–20:00 |
| 5569 View | MPN (Myeloproliferative Neoplasm) journal: A platform developed by MPN patients for MPN patients to track their disease, aid communication with healthcare team and create a dataset for patient data analytics | Ruben Mesa | Monday, December 8, 18:00–20:00 |
| 5572 View | Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the Italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV) | Tiziano Barbui | Monday, December 8, 18:00–20:00 |
| 5581 View | Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: <i>Post hoc</i> analyses of the SIMPLIFY-1 and MOMENTUM trials | Pankit Vachhani | Monday, December 8, 18:00–20:00 |
| 5589 View | A phase II study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – FRACTION study / IKF051 / gsg-MPN-006 | Susanne Isfort | Monday, December 8, 18:00–20:00 |
| 5590 View | Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2a | John Mascarenhas | Monday, December 8, 18:00–20:00 |



#ASH25

Follow us on X to keep up to date
with the latest from the congress

@MPN_Hub



Brought to you by

